appendix_6_focus_group_flyer_for_social_media_v1.0.pdf You are here
UCLH study: web-based video consultations
A study is being sponsored by UCL School of Pharmacy in London to look into the acceptability of web-based video consultations for patients who are receiving treatment for CML at University College London Hospital UCLH.
To help with this, we are looking for people with CML to take part in a focus group to help the study team understand if the opinions of UCLH patients are similar to those of the wider CML patient population.
Please see the flyer for more information and who to contact for more details
you gave CML, or know someone who does?
We are looking for people with CML to take part in a focus group as part of a study into the acceptability of web-based video consultations.
Who can take part?
You need to be:
- aged 18 or above
- receiving treatment for CML for a minimum of 12 months
- taking a type of medication called tyrosine kinase inhibitor (TKI) for your CML. For example imatinib (include Glivec® and Nibix®); nilotinib (Tasgina®); dasatinib (Sprycel®); bosutinib (Bosulif®) and ponatinib (Iclusig®)
- taking the same medication for the last 12 months (dose changes are acceptable)
What would it involve?
- The focus group should take no longer than 90 minutes
- We hope to run the focus group during January and February 2019
- The discussion will involve asking what your thoughts and opinions are on web-based video consultations
- You will receive a £10 Amazon voucher expenses for standard travel of up to £50 on the production of receipts (location to be confirmed)
How do I sign up?
If you are interested in participating or want further information, please contact Ms Terry Ng, Chief Investigator for the study at Terry.Ng@ucl.ac.uk or on 020 7753 5858. By doing so you are giving consent for her to use the contact details you provide to inform you about the study.
Acceptability of web-based video consultations in patients with CML, 18/0256 v1.0 10th August 2018
contact details you provide to inform you about the study.
This study has been approved by the London Bridge NHS Research Ethics Committee
(REC Ref: 18/LO/1532; IRAS:236595))